Using a small molecular chip assay, we found a selective MYC G4-binding drug with a benzofuran scaffold (D089) that can not only inhibit the expression of MYC in MM cell lines but also selectively induce G1 phase arrest in MYC-driven cancer cell lines containing the MYC G4 sequence. This evidence concerns the gene MYC and Miyoshi myopathy.